Cart
Account
Your Orders
Sign In
I am humbled and excited at what we accomplished at Synthego in the past year; we closed our Series B fundraise, continued to grow our amazing team, and leveraged our resources to launch Synthego’s full stack genome engineering workflow (from Design through our CRISPRevolution Guaranteed Editing Kits to ICE Analysis), taking an innovative, industry-leading approach.
Today we extend our accomplishments with the announcement that Dr. Jennifer Doudna, a pioneer and luminary in the field of genome engineering, is joining Synthego’s advisory board. Dr. Doudna co-discovered the programmable gene editing capabilities of CRISPR six years ago, paving the way for modern genome engineering.
Synthego is one of the most promising and necessary companies to emerge in the field of genome engineering,” said Jennifer Doudna. “By increasing access to this scientific advancement, Synthego will have an immediate impact on life sciences researchers and is poised to transform the industry by making the application of CRISPR simpler, faster, and more valuable to innovators previously unable to realize its full potential.
Read more in our press release.
Dr. Doudna’s expertise on Synthego’s advisory board will bring a new level of insight and understanding in our work towards standardizing CRISPR workflows with accessibility, precision and reproducibility. With her help, our product innovation will continue to enable customers to simplify and accelerate their genome engineering efforts.
At Synthego, we’re on a mission to bring the core principles of engineering to the life sciences, with the ultimate goal of helping make curative medicines accessible to everyone, by simplifying and accelerating the phases of research and drug development. The first step of the mission is to empower our customers with full stack genome engineering solutions, which support every step of their CRISPR workflow: design → edit → analyze. This opens the CRISPR field to all researchers, and brings them closer to an agile, automated, reproducible, and scalable experimental framework. Instead of spending weeks learning how to put together a robust CRISPR workflow, researchers at pharmaceutical and biotechnology companies or universities can focus on defining and implementing their CRISPR strategy to bring new therapeutics to market faster than ever and stay ahead of the competition.
Dr. Doudna’s visionary perspective aligns with Synthego’s goals of simplifying and accelerating genome engineering. All of our products, software tools, and services add to this journey of making medicines and cures accessible to everyone.
With this, the CRISPR revolution gains momentum, and our march towards standardizing and sharing knowledge in genome engineering to unlock the full potential of CRISPR gets closer to the goals. We’re proud to have Dr. Doudna by our side and look forward to what’s to come – we welcome her to the team!
